Efficacy of tadalafil on symptom-specific bother in men with lower urinary tract symptoms.

Abstract

INTRODUCTION:

This multicenter and prospective study was performed to evaluate the efficacy of tadalafil on patient-reported bother for each symptom in men with lower urinary tract symptoms (LUTS).

METHODS:

Men with LUTS received 5 mg of tadalafil daily for 4 weeks. We assessed change in symptom severity using both international prostate symptom score (IPSS), and overactive bladder symptom score (OABSS), as well as patient-reported quality of life (QOL: bother or satisfaction) for each symptoms using IPSS-visual analog scale (IPSS-VAS) and OABSS-VAS.

RESULTS:

We found significant improvements in total IPSS (P < 0.001), including voiding symptoms (P < 0.001), storage symptoms (P < 0.001), and QOL (P < 0.001). All VAS measures corresponding to symptoms in IPSS and OABSS also significantly improved (P < 0.001). The most bothersome symptoms for each patient at baseline evaluated by VAS measures significantly improved (P < 0.001). Patients whose most bothersome symptoms at baseline included IPSS-Q7 (nocturia) showed significantly smaller improvement of VAS measure after treatment than those without it (P = 0.024).

CONCLUSIONS:

Daily tadalafil significantly improved not only symptom severity of LUTS but also patient-reported QOL on each symptom.

• Authors: Naoki Hirahara, Shunji Harikai, Atsuko Fujihara, Yasuhiro Yamada, So Ushijima, Osamu Ukimura, KPUM-LUTS Research Group
• Journal: Lower urinary tract symptoms (Low Urin Tract Symptoms) Vol. 14 Issue 5 Pg. 393-400 (Sep 2022) ISSN: 1757-5672 [Electronic] Australia
• PMID: 35830962 (Publication Type: Journal Article, Multicenter Study)
• Copyright: © 2022 John Wiley & Sons Australia, Ltd.

Chemical References

• Phosphodiesterase 5 Inhibitors
• Tadalafil

Topics

• Humans
• Lower Urinary Tract Symptoms (drug therapy)
• Male
• Phosphodiesterase 5 Inhibitors (therapeutic use)
• Prospective Studies
• Prostatic Hyperplasia
• Quality of Life
• Tadalafil (therapeutic use)
• Treatment Outcome
• Urinary Bladder, Overactive (drug therapy)